Ocugen, Inc. (NASDAQ:OCGN) Q1 2021 Earnings Conference Call May 7, 2021 9:00 AM ET Company Participants Lisa DeScenza – Vice President-Integrated Communications-LaVoie Health Science Shankar Musunuri – Chairman, Chief Executive Officer and Co-Founder Sanjay Subramanian – Chief Financial Officer and Head-Corporate Development Conference Call Participants Keay Nakae – Chardan Zegbeh Jallah – ROTH Capital Robert LeBoyer – Noble Capital Swayampakula Ramakanth – H.C. Wainwright Kristen Kluska – Cantor Fitzgerald ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 __________________ ...

Ocugen, Inc. (NASDAQ:OCGN) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Lisa DeScenza – Vice President of Integrated Communications, LaVoie Health Science Shankar Musunuri – Chairman and Chief Executive Officer Sanjay Subramanian – Chief Financial Officer and Head of Corporate Development Conference Call Participants Keay Nakae – Chardan Zegbeh Jallah – ROTH Capital Partners Swayampakula Ramakanth – H.C. Wainwright Operator Good morning, and welcome to the Ocugen Conferenc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-K ___________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 _______________________ ...

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: March 2021 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, prod ...

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to fight COVID-19 NASDAQ: OCGN Corporate Deck: January 2021 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, product appr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 ______________ ...

Ocugen, Inc. (NASDAQ:OCGN) Q2 2020 Results Conference Call August 14, 2020 8:30 AM ET Company Participants Lisa DeScenza - VP of Integrated Communications, LaVoie Health Science Shankar Musunuri - Chairman and CEO Sanjay Subramanian - CFO Mohamed Genead - Acting CMO and Chair of Scientific Advisory Board Conference Call Participants Keay Nakae - Chardan Ramakanth Swayampakula - H.C. Wainwright Kristen Kluska - Cantor Fitzgerald Operator Good morning and welcome to the Ocugen Conference Call. [Operator Instr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 ___________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 __________________ ...